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1. Introduction 
Tumors of the intracranial neoplasms are devastating because they frequently cause 
mortality or morbidity. Current studies have shown that the immune system and genetics 
may play a critical role in development of different kinds of brain tumors. 
New insights into the causes and potential treatment of intracranial neoplasms have come 
from discovering connections with genes that control cell growth, differentation and 
development of brain cancer. Host immune response is one of key points in protection 
against brain tumor development.  
This section will outline what is known about molecular genetics, biology and 
immunogenetics of brain tumors.  
 We will first focus on main oncogenes which are seen in CNS tumors and try to find 
answer how do tumor-brain interactions contribute to development of brain tumor.   
 Finally we will discuss the mechanisms of immune activation and immune escape 
during an anti-tumor specific response, and new concepts for immunogenetic 
therapeutic intervention.. 
Thus, the data of immunogenetic pathways that are differentially involved in tumor 
initiation may represent a novel approach for the treatment of malignant brain tumors. 
2. Genetic and immunology of brain tumors 
Brain tumors are one of the leading cause of cancer mortality and remain difficult to cure 
despite advances in surgery and adjuvant therapy. Recent studies are focused on the 
molecular and cellular analysis of the bulk tumor mass. Glioma is the most common and 
mortal type of brain tumors (Kleihues et al., 2002). They are typically comprised of 
morphologically diverse cells that express a variety of neural lineage markers. Gliomas that 
share similar morphology and phenotype can have a very different prognosis and response 
to treatment. Alterations of multiple genes in the cell cycle and regulatory pathways plays 
an important role in tumorigenesis and causes to formation of subtypes (Singh et al., 2003). 
So researches in gene therapy have been often sice 1912 because no effective therapy is 
achieved until now in spite of traditional treatments including surgery, radiation therapy, 
and chemotherapy (Culver et al., 1992). Formerly, the brain has been regarded as an 
immunologically privileged organ site because it possesses a distinct blood-brain barrier 
(BBB) and lacks discrete lymphatic structures (Yoffey & Courtice, 1970).  Despite these 
factors minimizing central nervous system (CNS) immune function, a highly adapted 
system of immune surveillance presents, and effective immune responses can occur in the 
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CNS. Function of both the complement system (Bernheimer et al., 1988) and the antigen-
antibody system, including functional B cells (Aloisi et al., 1999; Sandberg-Wollheim et al., 
1986) have been found within the CNS. In the case of CNS pathologies resident antigen-
presenting cells (APC) of the CNS, microglia cells, undergo activation and upregulate both 
major histocompatibility complex (MHC) and costimulatory molecules,and also contribute 
to both CD41 and CD81 specific T-cell responses (Aloisi et al., 1998; Brannan & Roberts, 
2004; Hickey & Kimura, 1987; Hickey et al., 1991; Hickey, 2001; Krakowski & Owens, 2000). 
Actually a small number of lymphocytes are found in normal, healthy brain (Hickey & 
Kimura, 1987) however both resident lymphocytes and activated T cells have the capability 
to cross the BBB (Hickey & Kimura, 1987; Hickey et al., 1991; Hickey, 2001). Several 
lymphocytes also infiltrate the CNS in the presence of neoplasms (Han et al., 2010). Thus 
considering these factors new and more effective adjunctive treatments are needed. 
3. Brain tumors and oncogenes 
Oncogenes are functional mutations associated with cancer progression. They are derived 
from normal cellular genes called proto-oncogenes. The oncogenes that promote the tumor 
growth and development affecting mechanisms, such as cell proliferation, invasion, 
angiogenesis, and resistance to apoptosis by produced proteins are associated with the brain 
tumors. The protein synthesis which was gene product may increase or functional changes 
can be seen as a result of oncogenic mutation. 
The oncogenic activation associated with nervous system tumors is in the form of gene 
amplification and the number of cell-specific gene increases. The most common oncogenic 
change is the amplification of the epidermal growth factor receptor (EGFR) gene and the 
mutations of the TP53 gene (Ekstrand et al., 1991; Libermann et al., 1985; Wong et al., 1987). 
The EGFR gene that is activated by growth factors such as EGF, TGF-┙ is “transmembrane 
tyrosine kinase” codes.  
EGFR gene amplification was observed 40-50% of cases with glioblastoma multiforme, but it 
is rare in the anaplastic malignant astrocitoma (Brady et al., 1992; Ekstrand et al., 1991; 
Humphrey et al., 1990; Wong et al., 1987). This change is predictive for the malignancy 
degree of the astrocitomas (Ng & Lam, 1998). In malignant astrocitomas, the gene 
amplifications such as the MYCN, CDK4, MDM2, CCND1, and MET including the growth 
factors family of tyrosine kinase like EGFR were also determined (Bigner et al., 1987; .Fischer 
et al., 1995; He et al., 1994; Reifenberger et al., 1994).  
However, these amplifications were observed lesser than EGFR. In addition, the most 
common amplification was 10-15% CDK4 in malignant astrocitoma and glioblastoma. Each 
of these genes have been associated with the malignancy degree of glial tumors. The 
oncogenic changes were seen less than 10% in the other CNS tumors except for malignant 
astrocitomas. In medulloblastoma, the CMYC and MYCN amplifications were reported. 
Additionally, the ┚-catenin and TCF mutations were also detected in rare cases (Raffel et al., 
1990; Wasson et al., 1990; Zurawel et al., 1998). 
4. Gen therapy 
‘Gene therapy’ can be defined as the transfer of genetic material into a patient’s tumor cells 
by using stereotaxic injection. Up to present,various  treatment strategies utilizing gene 
therapy have been used, including gene transfer for modulating the immune system, 
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enzyme prodrug (‘suicide gene’) therapy, oncolytic therapy, replacement/ therapeutic gene 
transfer, and antisense therapy (Bansal& Engelhard, 2000). Many of them have been 
attempted both experimentally and in clinical trials (Iwami et al., 2010; Licht et al., 1996; Lun 
et al., 2010; Pedersini et al., 2010; Schmidt et al., 2011; Steffens et al., 2004; Yawata et al., 
2011). Mainly these approaches are based on previously established anti-neoplastic 
principles, like prodrug activating enzymes, inhibition of tumor neovascularization, and 
enhancement of the normally infirm anti-tumor immune response.  
The strategies of gene therapy can be categorized  as follows (Mut& Ziyal,2010). 
1. Enzyme prodrug: enzyme prodrug (‘suicide gene’) therapy. 
2. Oncolytic therapy, replacement. 
3. Transfer of potentially therapeutic genes such as tumor suprosser  (eg p53)  
4. Antisense therapy.  
5. Kemoprotection: Approaches which use the multidrug-resistance gene to protect bone 
marrow from myelosuppression following chemotherapy. Chemoresistance genes 
especially P-glycoprotein, the product of the multidrug-resistance (MDR1) gene, plays a 
major role in clinical treatment failure. 
6. Gene therapy for boosting the activity of the immune system againts tumor cells 
 
Approaches Administered  Genes 
Enzyme prodrug: enzyme prodrug 
(‘suicide gene’) therapy 
Suicide genes 
Immuno-gene therapy   Genes  of antigens and citokins  
Peplasman therapy Therapeutic genes 
Kemoprotection therapy  Multi-drug resistance  gene (MDR) 
Antisence therapy  Antisense DNA 
Oncolitic virus therapy  Oncolitic genes  
Table 1. Current treatment strategies used in  gene therapy. (Karaoglan &Turkmen,2010 )  
Immune gene therapy aims to enhance the T cell mediated immune responce againts to 
brain neoplasms by using genetically modified T cell therapy, vaccination therapy and 
cytokine therapy (Iwami et al., 2010). Cytotoxic  therapy  is mainly consist of either 
delivering  of gene or virus therapy  (Aboody et al., 2008; Aghi & Chiocca, 2006; Candolfi et 
al., 2009; Kroeger et al., 2010; Lawler et al., 2006). The most common  studied conditional 
cytotoxic transgene is Herpes Simplex Type 1 thymidine kinase (TK), which converts the 
prodrug ganciclovir (or valacyclovir) into the highly toxic deoxyguanosine triphosphate 
causing early chain termination of nascent DNA strands (Beltinger et al., 1999). The by-
stander effect of the TK approach is related to the passage of phosphorylated ganciclovir to 
neighboring cells through gap junctions, amplifying the cytotoxic effect of TK gene therapy 
(Mesnil & Yamasaki, 2000).  
4.1 Vectors in gene therapy 
Several viral and non-viral vectors have been engineered and used for gene transfer, both 
experimentally and clinically. 
Virotherapy is defined delivery of conditionally replicating viral vectors that solely replicate 
in tumor cells and kill them (Ferguson et al., 2010; Jiang et al., 2009; Markert et al., 2009). 
Viruses used for glioma gene therapy can be classified into 2 categories: replication-
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imcompetent viruses. In the first one, the vector is derived from a virus from which all or 
most of its genome has been removed, so minimizing the toxicity and retaining the gene 
delivery efficiency. In the second, only select viral genes are deleted or mutated so that 
viruses can replicate in and lyse tumor cells selectively (i.e., oncolytic viral therapy) (Iwami 
et al., 2010). 
4.1.1 Strategies in transgenic viruses (Iwami et al., 2010; Kozarsky & Wilson, 1993; 
Markert et al., 2009) 
1. Scientists add healthy functioning genes to cells that have damage or missing genes in 
order to substitute the bad non-working copy of the gene with a better copy of the 
working gene. The extraction of reproductive   are of virus was done initially. Genes 
have been added to and removed from the viruses so they cannot replicate on their 
own, but they can still break out of the tumor cells and invade nearby dividing cancer 
cells. 
2. Injecting of  the tumor cell with genes that can kill the  tumor cells. For instance, suicide 
genes are inserted into the tumor cells. A pro-drug or an inactive form of a toxic drug is 
administered to the patients, and this drug will kill off any tumor cells with the suicide 
genes in them. This method is called  enzyme prodrug (‘suicide gene’) therapy, Once 
inside the tumor cells, the viruses produce an enzyme that will turn an otherwise 
harmless drug into one that is toxic to the tumor cells. When the patient is treated with 
the drug gancyclovir, the enzyme converts it into something that is toxic to the tumor 
cells, and those cells die. 
3. Researchers can also transfer genetic materials into cancer cells by using ex-vivo 
techniques. Cancer cells are taken out of the body from the patient's blood or bone 
marrow surgically, and the necessary genes are added to them in the laboratory. 
4. Other method that is commonly used in laboratory is the in-vivo techniques. Virus or a 
plasmid is entirely necessary because gene cannot be directly inserted into a cell. The 
gene is inserted into the host's cell by using a vector. A vector acts as a bacteriophage or 
a plasmid (circular, small pieces of DNA) that can transfer genes from one cell to 
another. Vectors from the viruses adenoviruses are often used for gene therapy because 
viruses reproduce by inserting their genetic material into the cells they infect. 
Other transferring therapeutic genes to brain tumor cells are mostly used by HSV, retrovirus 
and adenovirus due to following key points. Application of adenovirus mediated gene 
therapy was successful in liver cell and respiratory epithelium (Kozarsky & Wilson, 1993; 
Kramm et al., 1995). Herpes simplex virus-thymidine kinase (HSV-tk) gene, had a good 
tendency to neuronal cells. Retroviral vectors have long survive in target cells (Kramm et al., 
1995). Oncolytic reovirus and measles viral vectors are under development for GBM 
virotherapy (Kroeger et al., 2010).  
Gene directed prodrug therapy utilizing the herpes simplex virus thymidine kinase gene 
was the first gene therapy experienced clinically (Mesnil & Yamasaki, 2000; Yawata et al., 
2011). The most frequent used paradigm is based on the activation of ganciclovir to a 
cytotoxic compound by a viral enzyme, thymidine kinase, which is expressed by tumor 
cells, after the gene has been introduced by a retroviral vector. This paradigm has proven to 
be a potent therapy with minimal side effects in several rodent brain tumor models, and has 
proceeded to phase 1 clinical trials (Kramm et al., 1995). 
Oncolytic viral therapy: This approach uses replication-competent viruses infect and lyse 
the target cells. An oncolytic vector should conditionally replicate within the target tumor 
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cells with minimal toxicity to the surrounding normal brain tissue. Oncolytic vectors are 
grouped as either mesogenic (moderately pathogenic, capable of producing viable progeny 
and infecting adjacent cells) or lentogenic (attenuated non-pathogenic, produces defective 
progeny and is incapable of spreading between tissues) (Dey et al., 2010). Replicating, 
oncolytic viruses have been developed from several species of viruses. The most common 
vectors are replicating herpes simplex virus (HSV), adenovirus and replication-competent 
retrovirus (RCR). Replicating herpes simplex virus (HSV) vectors have been tested for the 
treatment of malignant glioma (Grandi et al., 2009; Granelli-Piperno et al., 2000; Parker et al., 
2009). The common widely studied oncolytic HSV vector is G207, a genetically engineered 
HSV-1 (Markert et al., 2000). 
Tumor suppressor gene therapy: Mutation or inactivation of the p53 tumor suppressor gene 
is one of the early genetic alterations in the tumor progression of gliomas (Fults et al., 1992; 
von Deimling et al., 1992). Using a gene to encode a tumor-suppressor protein in glioma 
cells that is mutated or absent. Is the fundamental of this approach? TP53 is most common 
studied suppressor gene, whose mutations have been reported in 30-60% of malignant 
gliomas (Louis et al., 2001; Vousden & Lane, 2007). It is demonstrated that the replacement 
of wild-type p53 in tumor cells induced rapid cell death even in cells with the intact 
functional gene (Li et al., 1999; Roth, 2006).  
Antisense therapy: Antisense oligonucleotides are single strands of DNA or RNA that are 
complementary to a chosen sequence. Antisense oligonucleotides specific for insulin-like 
growth factor-1 (IGF-1) or transforming growth factor b2 (TGF-b2) have been used in 
various clinical studies (Tambuyzer et al., 2009; Vauleon et al., 2010).  
5. Non-viral methods  
Non-viral methods provide certain advantages over viral methods, such as simple large 
scale production and low host immunogenicity, however small levels of transfection and 
expression of the gene are a disadvantage of this methods (Iwami et al., 2010).  
1. Injection of naked DNA or naked PCR product,  
2. Physical methods to enhance delivery 
a. Electroporation 
b. Gene gun 
c. Sonoporation 
d. Magnetofection 
3. Chemical methods to enhance delivery 
Synthetic oligonucleotides, lipoplexes and polyplexes, dendrimers 
a. Hybrid methods: Combination of two or more techniques. For example virosomes 
are combine with liposomes using an inactivated HIV or influenza virus. 
Difficulties in gene therapy in brain tumors can be arranged as follows: (Mut & Ziyal, 2010). 
1. Difficulties to recognize tumor cells as target for attack. 
2. In order to inject gene cells into the specific region of the brain, to perform stereotactic 
brain surgery is mandatory. 
3. After the genes are injected into the region, there is the possibility that the viral vectors 
that are used to transfer the genetic material into the cell might infect healthy cells as 
well as brain tumors. 
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4. The new gene might also insert into the wrong location in the DNA, thus leading to 
harmful mutations of the DNA and triggering unwanted reaction by the immune 
system. 
5. The transferred genes can also be overexpressed by producing a lot of missing proteins. 
6. Finally, inflammation of the lining of the brain or infection can occur after the 
treatment. 
7. The negative side, on the other hand, is that the gene therapy will affect the 
development of the fetus in many unexpected ways like causing long-term illness or 
other side effects. The human gene pool can also be permanently affected by these gene 
alterations.  
6. Supressive factors of gliomas on immune system  
Gliomas can abstain immune system at different steps of antigen recognition and immune 
activation (Parney et al., 2000). Many glioma cells express low or defective levels of human 
leukocyte antigens (HLA) and also ave been found deficient in proper antigen presentation 
for cytotoxic and helper T-cell activation (Flügel et al., 1999). Inhibition of antigen 
presentation by microglia and macrophages in the tumor micro environment also causes to 
the tumors’ ability to escape immune detection.  
In gliomas, T cells, specifically the CD41 population, both in peripheral blood and in the 
tumor microenvironment, have depressed function (Roszman & Brooks, 1985; Roszman et 
al., 1985).
 
Innate helper T cells (CD41) reveal weak proliferative responses and dramatically 
lowered synthesis of the TH1 cytokine IL-2 (Das et al., 2008).
  
One hypothesis sugested that these are actually resident T cells passively infiltrating the 
tumor across a compromised BBB caused by the tumor; alternatively, they may represent a 
population that once was active but has been subsequently rendered inactive by the host of 
immunosuppressive mechanisms found in the tumor microenvironment (Han et al., 2010).  
Secretion of various immune inhibitory cytokines and molecules by glioma cells also plays 
an important role in glioma-associated immunosuppression. High levels of expression of 
TGF-b2, IL-10 and prostaglandin E2 are present in malignant gliomas (Couldwell et al., 
1992; Nitta et al., 1994). TGF-b2 mRNA is found in samples of glioblastome multiforme 
(GBM) (Bodmer et al., 1989). 
Iatrogenic factors may also cause a systemic immunosuppression in patients with glioma 
(Roszman & Brooks, 1985). Corticosteroids given in the treatment of tumor-associated 
edema may cause inhibition of cytokine production and sequestration of CD41 T cells 
(Barshes et al., 2004). Otherwise recent reports suggest, however, that at therapeutic doses 
corticosteroids may not interfere with immunotherapy (Fenstermaker & Ciesielski, 2004; 
Lesniak et al., 2004). 
Stimulation of microglia in the existence of tumor cells reduces the secretion of 
proinflammatory cytokines, such as tumor necrosis factor (TNF)-a, however also increases 
the secretion of the inhibitory cytokine interleukin (IL)-10 (Dix et al., 1999). 
7. Immunotherapy 
Immunotherapy is one of the new promising therapeutic approaches that can especially 
target tumour cells. Adoptive and active immunotherapies using lymphokine-activated 
killer cells, cytotoxic T cells, tumour-infiltrating lymphocytes, autologous tumour cells, and 
dendritic cells are mainly used in this approach (Prasad et al., 2004). 
www.intechopen.com
 
Genetic and Immunology of Brain Tumors  
 
9 
Microglial cells constitute the first step of defense for the brain. They migrate toward 
inflammatory zones and, after activation, possess phagocytic properties and synthesize 
several types of cytokines and chemokines (Tsurushima et al., 1999). They express a number 
of macrophage-associated markers and major histocompatability (MHC) antigens 
suggesting that they may actually function as APCs in the brain thus evidence suggests that 
antigen presentation cells (APCs) are indeed present in the brain (Cash & Rott, 1994).  
To date, it was generally suggested that immune reactions do not occur in the brain because 
of the blood-brain barrier (BBB) and the specific features of the brain such as the absence of 
conventional lymphatic vessels or the low level of circulating T cells. This hypthesiz is not 
true excacly. Cell based Immunotherapies are affective in brain tumors. Immune effector 
cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), 
cytotoxic T lymphocytes (CTL), etc., work together to defend the body against tumor by 
targeting abnormal antigens expressed on the surface of the tumor due to mutation. An 
adaptive immune response implies antigen recognition (Prasad et al., 2004). A variety of 
immunologically based strategies, including passive immunization and adoptive cellular 
immunotherapy (Fujimiya et al., 1999; Inoue et al., 1996; Kruse et al., 1990; Merchant et al., 
1997; Plautz et al., 1997; Plautz et al., 1998) local and systemic delivery of biological response 
modifiers (Dranoff et al., 1993; Färkkilä et al., 1994; Jean et al., 1998; Jean et al., 2004; Lichtor 
et al., 1995; Ohno et al., 2009; Thompson et al., 1996; Yu et al; 1993) and vaccination with 
parental and genetically modified tumor cells (Dranoff et al., 1993; Jean et al., 1998; Lichtor 
et al., 1995; Thompson et al., 1996; Ohno et al., 2009; Yu et al; 1993) have been attempted. 
7.1 Cytokine therapy 
Cytokines are a heterogeneous group of soluble small polypeptides or glycoproteins, which 
have either pro- or anti-inflammatory activity and immunosuppressive activity, depending 
on the microenvironments. The tumor microenvironment consists of a variable combination 
of tumor cells, endothelial cells and infiltrating leukocytes, such as macrophages, 
T-lymphocytes, natural killer (NK) cells, B-cells and antigen-presenting cells (APCs). 
Cytokine production acts as a means of communication in the tumor microenvironment 
(Giezeman-Smits et al., 2000). 
 
Several strategies for delivery of cytokines to the CNS have 
been studied, including injection/infusion of recombinant cytokines, vectors containing 
cytokine encoding genes, cells that secrete cytokines, or cytokines linked to toxins (Das et al., 
2008). 
7.2 Passive immunotherapy 
Passive immunotherapy includes serotherapy and adoptive immunotherapy. Serotherapy 
uses monoclonal antibodies to effect an antitumor response or to achieve very specific 
delivery of toxins, chemotherapy, or radiotherapy to the tumor cells. An important finding 
of its advantage is the identification of ‘‘tumor antigens,’’ specific antigens expressed on 
tumor cell surfaces but not on normal brain parenchyma (Ohno et al., 2009). Targeted 
glioma antigens have included tenascin, EGFR and its mutated form EGFRvIII, chondroitin 
sulfate, vascular endothelial growth factor (VEGF) receptor, neural cell adhesion molecule 
(NCAM), and hepatocyte growth factor/scatter factor (Hopkins et al., 1996). 
 In adoptive immunotherapy, immune cells activated ex vivo are administrated to the 
tumour-bearing patient. The activated cells are either injected directly into the tumour 
cavity or intravenously (Han et al., 2010). The first types of cells used for gliomas were 
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lymphocyte-activated killer (LAK) cells (Tsuboi et al., 2003). Cytotoxic T lymphocytes (CTL) 
can also be used. Autologous tumour cells (ATC) are generally used as antigen source 
(Holladay et al., 1996; Tsuboi et al., 2003). Another approach was to collect lymphocytes 
from lymph nodes (Holladay et al., 1996; Plautz et al., 1998; Plautz et al., 2000; Sloan et al., 
2000; Wood et al., 2000).  
Active immunotherapy involves strengthing patients’ immunity in vivo by vaccination 
against tumor antigen. Tumor vaccines for malignant glioma have been the focus of great 
interest currently. Successful development of glioma vaccines, however, requires proper 
presentation of tumor antigens and induction of effective, durable antigen-specific T cell 
immune response.A lot of antigen sources can be used for active immunotherapy such as 
intact tumour cells, tumour protein lysates, tumour-derived mRNA, peptides eluded from 
tumour MHC class I molecules, and synthetic peptides (Ishikawa et al., 2007; Okada et al., 
2007; Sloan et al., 2000; Steiner et al., 2004).  
8. Conclusion  
As brain tumor neoplasms constitute a formidable therapeutic challenge, gene and immuno 
therapy present powerful, novel opportunities for developing adjuvant therapies in brain 
cancer. However, more effective researches for adjuvant treatments of malignant gliomas 
are needed.  
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